



16 August 2005

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000
Dear Sir,

Resonance Health Signs Agreement with US Research Institute to Supply FerriScan[®]

Key Points

- **Multi-centre international clinical research program to use FerriScan**
- **FerriScan provided as an alternate to liver biopsy**
- **Potential for participating clinical sites to provide expanded FerriScan service**

Perth, Western Australia, 16 August 2005. Resonance Health (ASX:RHT) today announced its wholly-owned subsidiary, Resonance Health Analysis Services, has signed an agreement with the New England Research Institutes (NERI) to provide FerriScan[®] as part of clinical trials into the iron loading disorder thalassemia. The agreement will see FerriScan used by approximately 13 leading clinical sites in the US and other countries over the next four years.


FerriScan will be used to measure liver iron levels in patients with beta-thalassemia. The information provided by FerriScan will assist clinicians to determine the effects of iron overload on organ injury (including the heart), along with enabling the efficacy of new therapies for beta-thalassemia to be monitored. The work will be undertaken on behalf of the Thalassemia Clinical Research Network (TCRN).

Beta-thalassemia is a genetic blood disorder and a very severe and debilitating form of anaemia, resulting in iron overload due to the requirement for frequent blood transfusions.

Patients involved in this program having a FerriScan will no longer need to have a liver biopsy - a significant step forward in their disease management and quality of life outcomes.

Dr James Williams, Managing Director of Resonance Health said: "We are delighted to be involved in the important work being conducted by NERI/TCRN. The program will allow the clinicians involved to gain first-hand experience in the application of FerriScan to patients with thalassemia, and there is the potential for its use in the broader management of other iron loaded patients under their care."

Resonance Health recently announced the signing of a service agreement with Swiss Pharmaceutical company Novartis, a Collaboration Agreement with the DCA Group in Australia and is in discussions with US radiology providers to assist with the commercial roll-out of FerriScan. Completion of these agreements will position FerriScan to be widely accessible to leading clinicians in Australia, the US and Europe.



**Further information:
About 'Iron Overload' Conditions**

Having too much iron in the body and being unable to get rid of this excess is one of the world's most common hereditary disorders. The disorders, often collectively termed as 'Iron Overload', are generally classified as primary (e.g. hereditary hemochromatosis – HHC) or secondary (e.g. acquired – transfusional iron overload such as thalassemia). Approximately 11 million people globally, who have 'clinically significant' iron loading would benefit from improved diagnosis and management of their condition.

Hemochromatosis is a genetic disorder that causes iron deposition in the liver and other organs of the body, resulting in iron overload. The condition frequently remains undiagnosed because of lack of awareness, its long latency period and its non-specific symptoms. Thalassemia, a genetic blood disorder and a very severe and debilitating form of anaemia, also results in iron overload due to the requirement for frequent blood transfusions.

About Resonance Health Ltd

Resonance Health (ASX: RHT) is an Australian Healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI) related technology for the quantitative measurement of iron levels in the human body.

Our mission is to develop and market our technologies to assist in the diagnosis and management of patients suffering from iron-related conditions, whilst delivering significant added value for our MRI customers who deliver our service through their networks.

In 2005, RHT began the global commercial launch of FerriScan®, its world leading non-invasive tool for measuring liver iron levels.

The FerriScan service involves an MRI scan followed by off-site processing of the images by RHT using its patented methodology to generate the liver iron concentration result. MR data is transmitted electronically via a secure data process to the RHT analysis centre from anywhere in the world. The test requires no new equipment purchase at the MRI centre level.

FerriScan provides a significant improvement over current blood markers and invasive surgical procedures. This improvement leads to increased clinical efficiency and accuracy in diagnosis, in addition to allowing optimisation of treatment programs for iron-related disorders. FerriScan is now positioned to become a routine part of the clinical diagnosis and management of iron loading disorders as well as playing a major role in the testing and monitoring of drugs used to treat these conditions.

FerriScan has received regulatory clearance to be marketed in the USA, Australia, UK and Europe. Further information about Resonance Health and FerriScan® can be obtained from the following websites: www.resonancehealth.com and www.ferriscan.com.

Media and Investor Relations	Resonance Health
Rebecca Piercy Buchan Consulting T - +61 3 9866 4722 M – 0422 916 422 Email: rpiercy@bcg.com.au	Dr James Williams Managing Director Resonance Health Limited T - +61 8 9286 5300 M - 0409 050 519 Email: jamesw@ferriscan.com